Salvinorin A is a potent kappa opioid agonist isolated from the leaves of the Mexican Mint, Salvia divinorum. Recent studies have suggested this compound may be in part responsible for the hallucinogenic effects associated with the recreational use of the Salvia Divinorum extracts. The chemical structure of Salvinorin A, however, lacks key features historically associated with opiate activity, representing an entirely new class of opioid ligand. The work planned here, examines the molecular basis to Salvinorin A recognition and binding to the opioid receptors using a combination of chemical synthesis, molecular modeling, and ligand binding studies. Through this work, the potential use of Salvinorin A as a new opioid analgesic lead compound will be determined. This will be accomplished through the following key parts: 1) The determination of molecular basis to Salvinorin A binding and selectivity to the kappa opioid receptor. Using synthetic medicinal chemistry, a series of Salvinorin A analogs are synthesized and tested using ligand binding experiments. 2) The development of structure based models of Salvinorin A recognition that explain the structural activity relationship of synthetic analogs. Comparative molecular field analysis (CoMFA) techniques will be applied to identify potential sites of recognition within the opioid receptors and to propose synthetic modification of the Salvinorin A scaffold. 3) The identification of binding sites within the kappa opioid receptors that confer high affinity binding and selectivity of Salvinorin A. Ligand displacement studies will be performed using wild type and mutant opioid receptors to evaluate binding site models and provide insight to the design of Salvinorin A analogs. Initial targets for site directed mutagenesis will be derived from existing opiate structure-function studies and Salvinorin A receptor molecular models. Results of this work will direct further analog development of Salvinorin A (a next generation) and further define and refine our proposed computer binding and field models.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Small Research Grants (R03)
Project #
1R03DA017360-01
Application #
6718635
Study Section
Molecular, Cellular and Developmental Neurosciences 2 (MDCN)
Program Officer
Hillery, Paul
Project Start
2003-09-30
Project End
2005-06-30
Budget Start
2003-09-30
Budget End
2004-06-30
Support Year
1
Fiscal Year
2003
Total Cost
$71,750
Indirect Cost
Name
University of Mississippi
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
067713560
City
University
State
MS
Country
United States
Zip Code
38677
Venkitaramani, Deepa V; Paul, Surojit; Zhang, Yongfang et al. (2009) Knockout of striatal enriched protein tyrosine phosphatase in mice results in increased ERK1/2 phosphorylation. Synapse 63:69-81
Tashev, Roman; Moura, Paula J; Venkitaramani, Deepa V et al. (2009) A substrate trapping mutant form of striatal-enriched protein tyrosine phosphatase prevents amphetamine-induced stereotypies and long-term potentiation in the striatum. Biol Psychiatry 65:637-45
Kane, Brian E; McCurdy, Christopher R; Ferguson, David M (2008) Toward a structure-based model of salvinorin A recognition of the kappa-opioid receptor. J Med Chem 51:1824-30
Zhang, Yang; Venkitaramani, Deepa V; Gladding, Clare M et al. (2008) The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. J Neurosci 28:10561-6
Paul, Surojit; Olausson, Peter; Venkitaramani, Deepa V et al. (2007) The striatal-enriched protein tyrosine phosphatase gates long-term potentiation and fear memory in the lateral amygdala. Biol Psychiatry 61:1049-61
Hu, Yaer; Zhang, Yang; Venkitaramani, Deepa V et al. (2007) Translation of striatal-enriched protein tyrosine phosphatase (STEP) after beta1-adrenergic receptor stimulation. J Neurochem 103:531-41
Singh, Nidhi; Cheve, Gwenael; Ferguson, David M et al. (2006) A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist. J Comput Aided Mol Des 20:471-93
Kane, Brian E; Nieto, Marcelo J; McCurdy, Christopher R et al. (2006) A unique binding epitope for salvinorin A, a non-nitrogenous kappa opioid receptor agonist. FEBS J 273:1966-74